Company Profile

SANOFI INDIA LTD.

NSE : SANOFIBSE : 500674ISIN CODE : INE058A01010Industry : Pharmaceuticals & DrugsHouse : Sanofi India - MNC
BSE8576.4031.35 (+0.37 % )
PREV CLOSE (Rs.) 8545.05
OPEN PRICE (Rs.) 8550.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1125
TODAY'S LOW / HIGH (Rs.)8550.00 8725.00
52 WK LOW / HIGH (Rs.)7427.75 8999
NSE8575.40 17.3 (+0.2 % )
PREV CLOSE(Rs.) 8558.10
OPEN PRICE (Rs.) 8612.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 32776
TODAY'S LOW / HIGH(Rs.) 8552.00 8725.00
52 WK LOW / HIGH (Rs.)7424 8989

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 4.26
TTM EPS (Rs.) 251.88
P/E Ratio 34.05
Book Value (Rs.) 697.04
Face Value (Rs.) 10
MCap (Rs. in Mn) 197519.83
Price/Earning (TTM) 29.81
Price/Sales (TTM) 6.76
Price/Book (MRQ) 12.30
PAT Margin (%) 15.64
ROCE (%) 29.77
Incorporation Year : 1956

Management Info :

Aditya Narayan - Chairman Rajaram Narayanan - Managing Director

Registered Office :

Address : Sanofi House, 117-b,L&t Business Park,Saki Vihar Road, Powai,
Mumbai,
Maharashtra-400072

Phone :

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
28Jul07-28-2021$Sanofi India gets nod to transfer Nutraceuticals business to Universal Nutriscience Sanofi India gets nod to tra

Sanofi India’s board has approved a transaction for the slump sale and transfer of the company’s Nutraceuticals business, on a going concern basis to Universal Nutriscience for a consideration of Rs 5,870 million including debt like obligations (such as retirals and provision for sales returns), subject to customary working capital adjustments and post-closing adjustment in connection with certain contractual arrangements between the parties. Completion of the transaction is anticipated within the next 3 months, subject to fulfillment of conditions as set out in the Business Transfer Agreement.

The Nutraceuticals business of the company comprises 16 brands and 30 SKUs. These along with related business assets and liabilities including contracts, intellectual property rights, inventory, and all employees associated with this business will transition to Universal Nutriscience. This decision will help the Company to invest and focus on its strategic growth pillars, while allowing the Nutraceuticals business and the people associated with it, to significantly benefit in a company specialized in Nutraceuticals and Wellness. The Board of Directors of the company at its meeting held on July 27, 2021 has approved the same.

Sanofi India is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Sanofi India’s board has approved a transaction for the slump..
28Jul07-28-2021$Sanofi India surges on the BSE Sanofi India surges on the BSE

Sanofi India is currently trading at Rs. 8175.10, up by 215.20 points or 2.70% from its previous closing of Rs. 7959.90 on the BSE.

The scrip opened at Rs. 7985.00 and has touched a high and low of Rs. 8240.90 and Rs. 7959.00 respectively. So far 2533 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 8999.00 on 24-Aug-2020 and a 52 week low of Rs. 7427.75 on 27-Apr-2021.

Last one week high and low of the scrip stood at Rs. 8240.90 and Rs. 7842.00 respectively. The current market cap of the company is Rs. 18561.53 crore.

The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.28% and 11.33% respectively.

Sanofi India’s board has approved a transaction for the slump sale and transfer of the company’s Nutraceuticals business, on a going concern basis to Universal Nutriscience for a consideration of Rs 5,870 million including debt like obligations (such as retirals and provision for sales returns), subject to customary working capital adjustments and post-closing adjustment in connection with certain contractual arrangements between the parties. Completion of the transaction is anticipated within the next 3 months, subject to fulfillment of conditions as set out in the Business Transfer Agreement.

The Nutraceuticals business of the company comprises 16 brands and 30 SKUs. These along with related business assets and liabilities including contracts, intellectual property rights, inventory, and all employees associated with this business will transition to Universal Nutriscience. This decision will help the Company to invest and focus on its strategic growth pillars, while allowing the Nutraceuticals business and the people associated with it, to significantly benefit in a company specialized in Nutraceuticals and Wellness. The Board of Directors of the company at its meeting held on July 27, 2021 has approved the same.

Sanofi India is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Sanofi India is currently trading at Rs. 8175.10, up by 215.20..
28Jul07-28-2021$ Slump Sale And Transfer Of The Nutraceuticals Business Of The Company Slump Sale And Transfer Of
Please find enclosed announcement related to - Slump Sale and transfer of the Nutraceuticals business of the Company which is self explanatory for your records
Please find enclosed announcement related to - Slump Sale and t..
15Jul07-15-2021$Sanofi India informs about loss of share certificates Sanofi India informs about l
Sanofi India has informed that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.

The above information is a part of company’s filings submitted to BSE.

Sanofi India has informed that the Company has received communi..
12Jul07-12-2021$ Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 27Th July 2021 Board Meeting Intimation fo
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 27th July 2021; inter alia to consider the unaudited financial results for the quarter and half year ended 30th June 2021 (Q2).
Sanofi India Ltdhas informed BSE that the meeting of the Board..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 20
Net Profit17834776
Gross Profit 2426 6772
Operating Profit 26428029
Net Sales 789129019
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 3609.00 (5.00%)
M.Cap ( in Cr)
2229.65
Divi's Lab (BSE)
 5007.95 (1.62%)
M.Cap ( in Cr)
132945.34
Glaxosmithkline Phar (BSE)
 1682.75 (4.84%)
M.Cap ( in Cr)
28506.80
SMS Lifesciences (BSE)
 776.60 (7.57%)
M.Cap ( in Cr)
234.79
Procter&Gamble Healt (BSE)
 5492.75 (0.94%)
M.Cap ( in Cr)
9117.63
Shareholding Pattern More
FI/BANKS/INSURANCE 7.25 %
PROMOTERS 60.4 %
NON-INSTITUTION 11.33 %
MUTUAL FUNDS/UTI 10.13 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes